Kruger, Eliza
Aggio, Daniel
de Freitas, Hayley
Lloyd, Andrew
Funding for this research was provided by:
Ultragenyx Pharmaceutical
Article History
Accepted: 8 February 2023
First Online: 11 April 2023
Declarations
:
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Eliza Kruger, Daniel Aggio, Hayley de Freitas, and Andrew Lloyd. The first draft of the manuscript was written by Daniel Aggio, Hayley de Freitas, and Andrew Lloyd, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
: Manuscript data are available as electronic supplementary material.
: Eliza Kruger is an employee and shareholder of Ultragenyx Pharmaceutical Inc. Daniel Aggio, Hayley de Freitas, and Andrew Lloyd are employees of Acaster Lloyd Consulting Ltd. This research was funded by Ultragenyx Pharmaceutical Inc.
: This study was funded by Ultragenyx Pharmaceutical Inc.
: All study materials were submitted to the Western Institutional Review Board (WIRB) in the United States for ethical review. WIRB reviewed the study materials and determined the study was exempt from ethical review on 21 September 2020 (WIRB Submission Number: 2643053-44684192).
: All participants were provided with information about the study and asked to provide written informed consent prior to participation.
: All participants provided written informed consent for publication of the research results.
: Codes are available upon reasonable request to the corresponding author.